Couverture de HeartBeat Podcast

HeartBeat Podcast

HeartBeat Podcast

De : Mohammed Al-Qadami
Écouter gratuitement

À propos de ce contenu audio

 Welcome to the HeartBeat Podcast, your trusted source for the latest discoveries and advancements in cardiology. This podcast leverages advanced AI tools to analyze, summarize, and transform cutting-edge medical research into high-quality podcast episodes. While artificial intelligence plays a key role in producing and presenting these episodes, the content is carefully curated and crafted to ensure accuracy, reliability, and clarity. Whether you're a doctor, a student, or someone passionate about cardiology, this podcast offers insightful and inspiring episodes that combine the power of tecMohammed Al-Qadami Hygiène et vie saine Maladie et pathologies physiques
Les membres Amazon Prime bénéficient automatiquement de 2 livres audio offerts chez Audible.

Vous êtes membre Amazon Prime ?

Bénéficiez automatiquement de 2 livres audio offerts.
Bonne écoute !
    Épisodes
    • Impella CP: Can Microaxial Flow Pumps Redefine Cardiogenic Shock Treatment? Insights from the DanGer Shock Study

      Impella CP: Can Microaxial Flow Pumps Redefine Cardiogenic Shock Treatment? Insights from the DanGer Shock Study
      Feb 16 2025

      In this episode, we explore the DanGer Shock study, which investigated the efficacy of the microaxial flow pump Impella CP in reducing mortality and improving clinical outcomes in patients with STEMI-related cardiogenic shock. We delve into the study's design, statistical findings, clinical recommendations, and the future of mechanical circulatory support in cardiology, highlighting both the benefits and risks of this advanced technology as published in the NEJM.


      Links to the Podcast

      • Apple Podcast:⁠⁠⁠Listen on Apple Podcast⁠⁠⁠
      • Spotify:⁠⁠⁠Listen on Spotify⁠⁠⁠
      • Amazon Music:⁠⁠⁠Listen on Amazon Music⁠⁠⁠
      • YouTube:⁠⁠⁠Watch on YouTube⁠⁠⁠


      📚 Source:
      Study Title: Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock (DanGer Shock Trial)
      Publication Date: April 2024
      Journal: NEJM
      DOI:10.1056/NEJMoa2312572


      #MedicalPodcast #Cardiology #CardiogenicShock #ImpellaCP #DanGerShockStudy #MyocardialInfarction #MicroaxialFlowPump #CirculatorySupport #NEJM #HeartFailure #ClinicalResearch #HeartDevices #Podcast


      Afficher plus Afficher moins
      11 min
    • Breathing Easier: How Aficamten is Giving New Hope to HCM Patients

      Breathing Easier: How Aficamten is Giving New Hope to HCM Patients
      Feb 9 2025

      In this episode, we dive into the lives of patients with hypertrophic cardiomyopathy (HCM) and how Aficamten is offering them hope for a better future. From breathing easier to avoiding surgery, we’ll uncover the real impact of this new treatment backed by the SEQUOIA-HCM trial. If you care about heart health or know someone living with HCM, this one’s for you.


      Links to the Podcast

      • Apple Podcast:⁠⁠Listen on Apple Podcast⁠⁠
      • Spotify:⁠⁠Listen on Spotify⁠⁠
      • Amazon Music:⁠⁠Listen on Amazon Music⁠⁠
      • YouTube:⁠⁠Watch on YouTube⁠⁠


      📝Source:

      Study Title: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy (SEQUOIA-HCM Trial)

      Publication Date: May 13, 2024

      NEJM.org - SEQUOIA-HCM Trial

      🔗Full Study Details:NEJM - SEQUOIA-HCM Study
      🔗ClinicalTrials.gov:SEQUOIA-HCM NCT05186818


      #BreathingEasier #HeartHealth #Aficamten #NewHope #SEQUOIAHCM #CardiologyTalk #Podcast #RealImpact #MedicalBreakthroughs #BetterLiving
      Afficher plus Afficher moins
      16 min
    • Empagliflozin’s Impact: Long-Term Cardiorenal Protection for CKD Patients

      Empagliflozin’s Impact: Long-Term Cardiorenal Protection for CKD Patients
      Feb 2 2025

      In this episode, we explore the groundbreaking results of the EMPA-KIDNEY trial, a large-scale clinical study that highlights the long-term benefits of Empagliflozin (SGLT2 inhibitor) in patients with chronic kidney disease (CKD). We dive into how the treatment slowed disease progression, reduced cardiovascular deaths, and provided lasting benefits even after the therapy ended. Join us as we break down the study’s key findings, discuss their real-world implications, and uncover what makes this treatment a game-changer for CKD management.

      🔗 Full Study Details: NEJM - EMPA-KIDNEY Study
      🔗 ClinicalTrials.gov: EMPA-KIDNEY NCT03594110


      Links to the Podcast

      • Apple Podcast: ⁠Listen on Apple Podcast⁠
      • Spotify: ⁠Listen on Spotify⁠
      • Amazon Music: ⁠Listen on Amazon Music⁠
      • YouTube: ⁠Watch on YouTube⁠


      #Podcast #Empagliflozin #ChronicKidneyDisease #CKDManagement #EMPA_KIDNEY_Study #SGLT2Inhibitors #RenalHealth #CardioRenalProtection #ClinicalResearch #MedicalBreakthroughs #LongTermBenefits
      Afficher plus Afficher moins
      16 min
    Aucun commentaire pour le moment